Balance Sheet: Liabilities and Stockholders’ Equity

The balance sheet provides creditors, investors, and analysts with information on company resources (assets) and its sources of capital (its equity and liabilities). It normally also provides information about the future earnings capacity of a company assets as well as an indication of cash flows that may come from receivables and inventories.

Liabilities represents obligations of a company arising from past events, the settlement of which is expected to result in an outflow of economic benefits from the entity.

Biogen Inc., consolidated balance sheet: liabilities and stockholders’ equity

US$ in thousands

	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Current portion of notes payable	999,100)	—)	1,495,800)	—)	3,200)
Taxes payable	174,700)	142,000)	71,400)	63,500)	68,200)
Accounts payable	589,200)	454,900)	530,800)	370,500)	395,500)
Revenue-related reserves for discounts and allowances	802,100)	1,080,600)	1,001,100)	874,700)	572,000)
Collaboration expenses	324,700)	389,900)	281,600)	261,600)	183,700)
Employee compensation and benefits	345,100)	333,800)	309,100)	320,900)	297,700)
Royalties and licensing fees	234,700)	218,500)	220,900)	224,700)	206,700)
Derivative liabilities	10,800)	181,500)	6,700)	—)	—)
Current portion of contingent consideration obligations	—)	149,600)	148,400)	444,800)	844,600)
Other	817,800)	791,400)	798,000)	734,500)	796,600)
Accrued expense and other	2,535,200)	3,145,300)	2,765,800)	2,861,200)	2,901,300)
Current liabilities	4,298,200)	3,742,200)	4,863,800)	3,295,200)	3,368,200)
Notes payable, excluding current portion	6,274,000)	7,426,200)	4,459,000)	5,936,500)	5,935,000)
Deferred tax liability	694,500)	1,032,800)	2,810,800)	1,636,200)	122,600)
Long-term operating lease liabilities	330,400)	402,000)	412,700)	—)	—)
Other long-term liabilities	1,320,500)	1,329,600)	1,348,900)	1,389,400)	1,628,700)
Long-term liabilities	8,619,400)	10,190,600)	9,031,400)	8,962,100)	7,686,300)
Total liabilities	12,917,600)	13,932,800)	13,895,200)	12,257,300)	11,054,500)
Preferred stock, par value $0.001 per share	—)	—)	—)	—)	—)
Common stock, par value $0.0005 per share	100)	100)	100)	100)	100)
Additional paid-in capital	68,200)	—)	—)	—)	97,800)
Accumulated other comprehensive loss	(106,700)	(299,000)	(135,200)	(240,400)	(318,400)
Retained earnings	13,911,700)	13,976,300)	16,455,400)	16,257,000)	15,810,400)
Treasury stock, at cost	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)	(2,977,100)
Total Biogen Inc. shareholders’ equity	10,896,200)	10,700,300)	13,343,200)	13,039,600)	12,612,800)
Noncontrolling interests	63,500)	(14,200)	(4,100)	(8,000)	(14,700)
Total equity	10,959,700)	10,686,100)	13,339,100)	13,031,600)	12,598,100)
Total liabilities and equity	23,877,300)	24,618,900)	27,234,300)	25,288,900)	23,652,600)

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

Download chart

Balance sheet item	Description	The company
Current liabilities	Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.	Biogen Inc. current liabilities decreased from 2019 to 2020 but then slightly increased from 2020 to 2021.
Long-term liabilities	Amount of obligation due after one year or beyond the normal operating cycle, if longer.	Biogen Inc. long-term liabilities increased from 2019 to 2020 but then decreased significantly from 2020 to 2021.
Total liabilities	Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.	Biogen Inc. total liabilities increased from 2019 to 2020 but then decreased significantly from 2020 to 2021.
Total Biogen Inc. shareholders’ equity	Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.	Biogen Inc. total Biogen Inc. shareholders’ equity decreased from 2019 to 2020 but then slightly increased from 2020 to 2021.

Biogen Inc. (NASDAQ:BIIB)

Balance Sheet: Liabilities and Stockholders’ Equity